For research use only. Not for therapeutic Use.
GBD-9(CAT: I040916) is a dual-mechanism degrader that targets both Bruton’s tyrosine kinase (BTK) and G1 to S phase transition 1 (GSPT1) by utilizing the E3 ligase cereblon (CRBN). As a PROTAC (proteolysis-targeting chimera), GBD-9 induces the degradation of BTK by recruiting CRBN, while acting as a molecular glue to facilitate the degradation of GSPT1. BTK is a key regulator in B-cell receptor signaling, and its dysregulation is implicated in several cancers, while GSPT1 is involved in the termination of translation. By degrading these targets, GBD-9 effectively inhibits cancer cell growth, making it highly relevant for Cancer Disease Research and offering potential for targeted cancer therapies.
| CAS Number | 2864408-92-2 |
| Synonyms | 5-[[9-[3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-9-oxononyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| Molecular Formula | C44H47N9O6 |
| Purity | ≥95% |
| IUPAC Name | 5-[[9-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-9-oxononyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| InChI | InChI=1S/C44H47N9O6/c45-40-38-39(28-15-18-32(19-16-28)59-31-12-6-5-7-13-31)50-53(41(38)48-27-47-40)30-11-10-24-51(26-30)37(55)14-8-3-1-2-4-9-23-46-29-17-20-33-34(25-29)44(58)52(43(33)57)35-21-22-36(54)49-42(35)56/h5-7,12-13,15-20,25,27,30,35,46H,1-4,8-11,14,21-24,26H2,(H2,45,47,48)(H,49,54,56) |
| InChIKey | DCJYQURCBHSFEP-UHFFFAOYSA-N |
| SMILES | C1CC(CN(C1)C(=O)CCCCCCCCNC2=CC3=C(C=C2)C(=O)N(C3=O)C4CCC(=O)NC4=O)N5C6=NC=NC(=C6C(=N5)C7=CC=C(C=C7)OC8=CC=CC=C8)N |
